Pfizer Inc. (NYSE:PFE) Shares Purchased by Capital Asset Advisory Services LLC

Capital Asset Advisory Services LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 1.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,623 shares of the biopharmaceutical company’s stock after acquiring an additional 460 shares during the period. Capital Asset Advisory Services LLC’s holdings in Pfizer were worth $1,689,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alpha DNA Investment Management LLC acquired a new position in Pfizer during the 4th quarter worth approximately $26,000. Orion Capital Management LLC purchased a new stake in Pfizer in the 4th quarter valued at $29,000. Merrion Investment Management Co LLC purchased a new stake in Pfizer in the 4th quarter valued at $30,000. EMC Capital Management purchased a new stake in Pfizer in the 4th quarter valued at $37,000. Finally, Mach 1 Financial Group Inc. purchased a new stake in Pfizer in the 4th quarter valued at $37,000. Institutional investors own 64.22% of the company’s stock.

A number of equities analysts have commented on PFE shares. TheStreet upgraded shares of Pfizer from a “c+” rating to a “b-” rating in a research report on Monday, May 3rd. Barclays upped their price objective on shares of Pfizer from $37.00 to $40.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 5th. Morgan Stanley upped their price objective on shares of Pfizer from $38.00 to $42.00 and gave the stock an “equal weight” rating in a research report on Monday, May 10th. Mizuho restated a “neutral” rating and set a $42.00 price objective on shares of Pfizer in a research report on Wednesday, May 12th. Finally, Berenberg Bank restated a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a research report on Tuesday, June 15th. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $40.20.

NYSE PFE traded up $0.10 during mid-day trading on Thursday, hitting $39.15. The company’s stock had a trading volume of 148,816 shares, compared to its average volume of 30,052,848. Pfizer Inc. has a 52-week low of $31.61 and a 52-week high of $43.08. The company has a fifty day moving average price of $39.29. The company has a quick ratio of 1.16, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. The stock has a market cap of $219.15 billion, a price-to-earnings ratio of 19.92, a P/E/G ratio of 1.43 and a beta of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.78 by $0.15. Pfizer had a net margin of 22.09% and a return on equity of 24.55%. The firm had revenue of $14.58 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same quarter last year, the firm posted $0.80 earnings per share. Pfizer’s revenue for the quarter was up 44.6% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 3.69 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 7th. Shareholders of record on Friday, July 30th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 3.98%. Pfizer’s dividend payout ratio (DPR) is 70.27%.

In other news, SVP Jennifer B. Damico sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 5th. The shares were sold at an average price of $40.82, for a total transaction of $102,050.00. Following the completion of the sale, the senior vice president now owns 13,748 shares of the company’s stock, valued at $561,193.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.05% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

See Also: Understanding debt-to-equity ratio in fundamental analysis

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.